Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam
Cefepime/zidebactam and aztreonam/avibactam hold great promise for the treatment of CR-hvKP infections. Our findings will not only effectively address the challenge of CR-hvKP resistance, but also provide evidence to support the optimization of clinical therapeutic strategies and further promote the development and application of novel antimicrobial drugs.
Authors
- Xun Jia
- Yulian Li (ORCID: https://orcid.org/0009-0009-9269-9093)
- Huinan Mao
- Yong Li (ORCID: https://orcid.org/0000-0003-4038-0493)
- Li Zhang (ORCID: https://orcid.org/0000-0003-1152-8962)
- Dan Li
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- West China Hospital of Sichuan University (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1186/s12879-026-12824-7
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00